Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA damage response inhibitors: An avenue for TNBC treatment.

Biochimica et biophysica acta. Reviews on cancer - 1 Apr 2021

Jin Juan, Tao Zhonghua, Cao Jun, Li Ting, Hu Xichun

Abstract excerpt

The DNA damage response (DDR) is critical for the maintenance of genomic stability by sensing DNA damage, regulating cell cycle and initiating DNA repair. Drugs targeting DDR pathways have been increasingly exploited in treating various tumors. Triple negative breast cancer (TNBC) is a highly heterogeneous and aggressive tumor with constitutive activation of oncogenes, inducing replication stress and DNA damage,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Repair
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Molecular Targeted Therapy

Share to Mutation

Share to Signal Transduction

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 33556453
DOI: 10.1016/j.bbcan.2021.188521

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA damage response inhibitors: An avenue for TNBC treatment.PMID 33556453Read ↗

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising TargetsSemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response in CancerSemantic proximity Read ↗

Targeting DNA repair pathway in cancer: Mechanisms and clinical applicationSemantic proximity Read ↗

Targeting the DNA repair pathway for breast cancer therapy: Beyond the molecular subtypesSemantic proximity Read ↗

DNA Damage Response in Cancer Therapy and Resistance: Challenges and OpportunitiesSemantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

Exploiting DNA repair defects in triple negative breast cancer to improve cell killingSemantic proximity Read ↗

DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directionsSemantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.